TABLE 22.
Reference study population design | Outcome definition | Population size (n) case/control | Arsenic exposure | Results | Additional information/confounders |
---|---|---|---|---|---|
Wang et al. (2016) Nanjing Medical University, China Case–control |
Unexplained male infertility |
Cases: 101 infertile men with normal semen whose wives were evaluated to have normal reproductive function Controls: 61 fertile men with normal semen whose wives had successful pregnancy in last 3 months |
Urinary concentration (μg/g creatinine), Medians, Cases – Controls Asi III 4.10–3.97 Asi V 71.59–0.63 AsB 12.03–7.80 MMAV 4.20–2.93 DMAV 28.23–18.30 u‐tiAs 74.87–5.46 |
Adjusted OR (95% CI) 4th versus 1st quartile Asi III 0.59 (0.19–1.83) Asi V 36.51 (8.25–161.7) AsB 2.23 (0.70–7.12) MMAV 1.97 (0.57–6.77) DMAV 1.27 (0.40–4.03) u‐tiAs 10.17 (2.72–38.11) |
Adjusted for age, BMI, drinking and smoking |
Abbreviations: As(III), arsenite; As(V), arsenate; AsB, arsenobetaine; BMI, body mass index; CI, confidence interval; DMA(V), dimethylarsinic acid; iAs, inorganic arsenic; MMA(V), monomethylarsonic acid; n, number; OR, odds ratio; u‐tiAs, total urinary iAs (sum of iAs and its methylated metabolites MMA and DMA).